Research Fields
The mission of Nexpharm Korea for the next generation is human
Pipelines
| Item | Project | Indication | Research | Non-clinical study | Clinical study | ||
|---|---|---|---|---|---|---|---|
| Phase I | Phase II | Phase III | |||||
| Incrementally modified drugs | Rifaximin - New crystalline form |
IBS | |||||
| Esomeprazole - Different Preparation - New sustained release |
GI Trouble | ||||||
| New natural substances | G47 Extract (Patent. 10-2013-0028281) |
Hyperlipidemia | |||||
| G46 Extract (Patent.10-2013-0064205) |
Osteoarthritis | ||||||
| New synthetic compounds | N-Trance compound (Patent.10-2013-0064204) |
Osteoarthritis | |||||
| Biologicals | TRAP80 (Patent.10-1341200) |
Atherosclerosis | |||||
R&D Achievements
- Development of evaluation method of in-soluble drugs through functional classification of biofused materials.
- Identification of a pharmaceutical composition for the prevention or treatment of hyperlipidemia containing Amomi Tsao-ko extract as an active ingredient
- Development of a composition for preventing or treating inflammatory diseases containing dihydrodiciconyl peroxide alcohol as an active ingredient extracted from tribulus terrestris
- Development of anti-obesity composition containing Saringosterol
- Development of a composition for inhibiting angiogenesis containing mulberry extract as an active ingredient